Real-world data demonstrates that a subset of node-negative (N0) breast cancer patients with high-risk features has a recurrence and mortality rate nearly identical to that of node-positive (N1) patients. This finding justifies intensifying adjuvant therapy with agents like CDK4/6 inhibitors for this seemingly lower-risk group, as was done in the NATALEE trial.

Contrary to the belief that HR+ breast cancer primarily carries a late recurrence risk, data shows high-risk, node-positive patients can be extremely aggressive early on. With recurrence rates up to 29.1% within five years, this subgroup can perform as poorly, or even worse, than triple-negative breast cancer, highlighting the need for intensive adjuvant therapy.

Despite low individual recurrence rates, the vast number of women diagnosed with early-stage breast cancer means they account for most deaths. The annual proportion of deaths from stage 2 disease rose from 26% to 40%, while stage 1 accounts for another 23%. This highlights the need for better monitoring, like ctDNA, in this population.

Emerging data from major trials shows that ctDNA clearance during neoadjuvant therapy and negative post-surgical MRD status are strong predictors of improved survival. MRD positivity, in contrast, is associated with worse biology and rapid progression.

While nomograms are useful for quantifying risk in primary CSCC tumors, their predictive power diminishes significantly once a patient has a regional recurrence. Clinicians should use them cautiously in the recurrent setting, as their original design and validation are based on primary tumors.

In a subset analysis of the high-risk MONARCH-E trial, an inferred Oncotype score did not identify which patients benefited from the CDK4/6 inhibitor abemaciclib. This indicates that while such scores assess prognostic risk and guide chemotherapy decisions, they are not predictive biomarkers for selecting patients for this targeted therapy.

The RSClin tool integrates a patient's Oncotype DX score with their unique clinical-pathologic features, such as tumor size and grade. This provides a more accurate and personalized risk assessment, as the same genomic score can represent significantly different prognoses for patients who have low versus high clinical risk factors.

In neoadjuvant breast cancer treatment, patients with residual cancer post-therapy remain at high risk of recurrence (10-20%) even if their ctDNA tests are negative. This finding suggests that the physical presence of residual disease is a critical factor, and ctDNA status alone cannot justify forgoing additional adjuvant therapy in this cohort.

Experts warn against over-interpreting a single negative ctDNA test after surgery, clarifying that these patients still face a significant 25-30% risk of recurrence. The biomarker's true prognostic power comes from serial testing that shows a patient remains persistently negative over time.